8-K: CAMP4 Therapeutics Stockholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

CAMP4 Therapeutics Corporation announced the successful election of its Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 annual meeting of stockholders.

Summary

• CAMP4 Therapeutics Corporation held its 2025 annual meeting of stockholders on June 11, 2025.
• Four Class I directors – James Boylan, Amir Nashat, ScD, Andrew J. Schwab, and Douglas Williams, PhD – were elected to serve three-year terms until the 2028 annual meeting.
• The election results showed strong support for the director nominees, with James Boylan receiving 15,802,709 'For' votes, Amir Nashat and Andrew J. Schwab each receiving 16,050,167 'For' votes, and Douglas Williams, PhD receiving 16,700,927 'For' votes.
• The appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 17,900,199 'For' votes.

Sentiment

Score: 7

Explanation: The sentiment is positive as all corporate governance proposals passed successfully with strong shareholder support, indicating stability and adherence to standard procedures. No negative or unexpected outcomes were reported.

Positives

• All proposed Class I director nominees were successfully elected with significant shareholder support, indicating board stability.
• The ratification of Ernst & Young LLP as the independent auditor ensures continuity in financial oversight and compliance.

Future Outlook

The document does not contain specific forward-looking statements or financial guidance beyond the term of the elected directors and the auditor's engagement for the current fiscal year.

Management Comments

• The report was signed by Kelly Gold, Chief Financial Officer of CAMP4 Therapeutics Corporation.

Industry Context

This 8-K filing details routine corporate governance matters for a publicly traded biotechnology company, consistent with standard annual meeting disclosures across the industry. The successful election of directors and ratification of auditors are common procedural events.

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes determined the composition of the Class I directors and ratified the independent auditor, directly impacting corporate governance and oversight.
• Management/Board: The re-election of directors provides continuity and a clear mandate for their ongoing roles.

Next Steps

• The elected Class I directors will serve for a three-year term until the 2028 annual meeting of stockholders.
• Ernst & Young LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

CAMP4 Therapeutics, Annual Meeting, Stockholders, Board of Directors, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K, Biotechnology